Eisai and Purdue Pharma begin Phase II study of lemborexant to treat irregular sleep-wake rhythm disorder

Eisai and Purdue Pharma have begun the Phase II clinical study of lemborexant (E2006) to treat patients with mild-to-moderate Alzheimer's disease (AD) who suffer from irregular sleep-wake rhythm disorder (ISWRD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news